Should These 3 Biotech Stocks Be Excised From Your Portfolio?
When it comes to the three biotech stocks discussed in today’s article, all of which are down 45% or more from their 52-week highs, should…
When it comes to the three biotech stocks discussed in today’s article, all of which are down 45% or more from their 52-week highs, should…
After a challenging first quarter of 2021 for biotech investors, what does the second quarter – and, beyond that, the second half of 2021 –…
There’s a severe shortage of semiconductors – the worst shortage in 30 years according to one analysis – and it’s being felt across many industries,…
“Investing in any kind of stock can be risky. But investing in clinical-stage biotech stocks can be extraordinarily risky,” acknowledge the authors of today’s article.…
“With West Texas Intermediate (WTI) crude trading near the $60 a barrel level, and expected to go even higher this summer, these could all have…
In screening for stocks with the potential of generating solid returns, the author of today’s article uses a high earnings yield as their primary criterion,…
The company featured in today’s article is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain – and…
“Scared money runs and misses out on profits, while smart money is always poised to pounce on temporary disconnects,” declares the author of today’s article…
“As corporate budgets start to thaw this year along with a gradually reopening economy, AI applications are expected to receive plenty of attention,” notes the…
Amid the ongoing opioid crisis, the need for non-opioid pain management solutions is increasing. As a provider of pre- and post-surgical non-opioid pain management solutions,…